According to @StockMKTNewz, Novo Nordisk (NVO) shares have climbed 70% since the approval of Wegovy for weight loss in the United States in June 2021. This strong performance highlights significant investor confidence in Novo Nordisk’s pharmaceutical pipeline and the growing demand for weight loss treatments. Traders should note that such a sustained rally can attract further institutional interest and could impact related healthcare equities. Additionally, the surge in NVO may influence broader sentiment toward biotech and pharma-linked crypto tokens, especially those tracking health sector performance. Source: @StockMKTNewz.